The Post-Finasteride Syndrome Foundation’s primary mission is to facilitate research on the characterization, underlying biologic mechanisms, and potential treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS, and providing support for patients suffering from the condition.
Adverse drug reaction reports worldwide
PFS research studies published
Known suicides worldwide
Doctors & researchers speaking out
Nations warning of PFS
Jan. 22, 2022 Dear Friends: A new documentary examining three young men’s reactions to rapidly thinning locks—shaving, transplanting and finasteride—features an interview with eminent PFS researcher Roberto Cosimo Melcangi, PhD. Titled Plötzlich kahl (Suddenly Bald) the 30-minute film by Gustav Hofer (English-subtitled version here) debuted last month on SRF, the largest German-language broadcaster in Switzerland. […]
Jan. 10, 2022 Dear Friends: After enduring decades of symptoms that ran the gamut from tooth loss to testicular cancer, Ryan Clark prompted his nation’s drug agency to take a telemed to task for failing to adequately disclose finasteride’s dangers. And though he’d hoped for more significant action, the 54-year-old PFS patient from the northeast […]
Editorial in leading journal, meanwhile, criticizes FDA for not making Merck conduct new safety studies when persistent ED signal emerged Nov. 20, 2021 Dear Friends: A decade after the first peer-reviewed article on persistent adverse sexual effects in finasteride patients appeared in medical literature, the first-ever diagnostic criteria for PFS has followed suit. We have […]
Sept. 9, 2021 Dear Friends: The Post-Finasteride Syndrome Foundation, represented by consumer rights advocacy group Public Citizen, yesterday filed a lawsuit in Washington, DC, federal court compelling the US Food and Drug Administration to act on our Citizen Petition. Facts laid out in the eight-page complaint include: The “most serious risk of 1 mg finasteride […]
Aug. 4, 2021 Dear Friends: For several years now, our patient manager, Philip Roberts, has been telling me he feels like Radar O’Reilly on M*A*S*H. Fans of the dark Korean War comedy will recall that often after endless hours of stitching up battlefield casualties—and having just flopped onto their cots—the doctors would be interrupted by […]
Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.
An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use: insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under 40 years of age who use finasteride for alopecia are at risk of suicide if they develop persistent sexual adverse effects and insomnia.
—Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020
Two subjects—eight percent—committed suicide during or after the study.
While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy… Two subjects (8%) committed suicide during or after the study.
—Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia: Translational Andrology and Urology, April 2020
Health care professionals should…conduct a full evaluation and a…risk-benefit assessment for patients before each prescription of finasteride.
As prescribers, our primary duty is to do no harm. Health care professionals should keep themselves abreast of these potential signals and, accordingly, conduct a full evaluation and a detailed, personalized risk-benefit assessment for patients before each prescription of finasteride.
—Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia: JAMA Dermatology, November 2020
This drug for young men must be taken off the market.
As of 2018, 15,000 cases of adverse reactions to finasteride were reported to the WHO—which is a huge number to begin with. And the interesting thing is that the average age of this group was 32 to 34 years old… This drug for young men must be taken off the market.
—Documentary on German network NDR titled Side Effects of Finasteride Are Underestimated: January 25, 2021